These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 15664056)

  • 1. A new cell-based assay for measuring the forward mutation rate of HIV-1.
    Huang KJ; Wooley DP
    J Virol Methods; 2005 Mar; 124(1-2):95-104. PubMed ID: 15664056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of direct repeat deletion in a human immunodeficiency virus type 1 vector during reverse transcription in human cells.
    An W; Telesnitsky A
    Virology; 2001 Aug; 286(2):475-82. PubMed ID: 11485415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. StpC-based gene therapy targeting latent reservoirs of HIV-1.
    Turner LS; Tsygankov AY; Henderson EE
    Antiviral Res; 2006 Dec; 72(3):233-41. PubMed ID: 16891001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
    Chang LJ; Liu X; He J
    Gene Ther; 2005 Jul; 12(14):1133-44. PubMed ID: 15750613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nucleoside analogs 4'C-methyl thymidine and 4'C-ethyl thymidine block DNA synthesis by wild-type HIV-1 RT and excision proficient NRTI resistant RT variants.
    Boyer PL; Julias JG; Ambrose Z; Siddiqui MA; Marquez VE; Hughes SH
    J Mol Biol; 2007 Aug; 371(4):873-82. PubMed ID: 17597154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
    Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
    J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
    Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
    J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus.
    Vandekerckhove L; Christ F; Van Maele B; De Rijck J; Gijsbers R; Van den Haute C; Witvrouw M; Debyser Z
    J Virol; 2006 Feb; 80(4):1886-96. PubMed ID: 16439544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replicative fidelity of lentiviral vectors produced by transient transfection.
    Laakso MM; Sutton RE
    Virology; 2006 May; 348(2):406-17. PubMed ID: 16469344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells.
    Yam P; Jensen M; Akkina R; Anderson J; Villacres MC; Wu J; Zaia JA; Yee JK
    Mol Ther; 2006 Aug; 14(2):236-44. PubMed ID: 16647299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility.
    Paolucci S; Baldanti F; Dossena L; Gerna G
    Antiviral Res; 2006 Mar; 69(3):181-5. PubMed ID: 16460817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
    Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
    J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations.
    Li J; Li L; Li HP; Zhuang DM; Liu SY; Liu YJ; Bao ZY; Wang Z; Li JY
    Chin Med J (Engl); 2009 May; 122(9):1081-6. PubMed ID: 19493444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates.
    Dudley DM; Gao Y; Nelson KN; Henry KR; Nankya I; Gibson RM; Arts EJ
    Biotechniques; 2009 May; 46(6):458-67. PubMed ID: 19480640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of human immunodeficiency virus type 1 vector cis- and trans-acting elements production by means of Semliki Forest virus.
    Del Vecchio C; Calistri A; Lombardi G; Celegato M; Biasolo MA; Palù G; Parolin C
    Gene Ther; 2009 Feb; 16(2):279-90. PubMed ID: 19037240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
    Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
    J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrocyclin RC-101 overcomes cationic mutations on the heptad repeat 2 region of HIV-1 gp41.
    Fuhrman CA; Warren AD; Waring AJ; Dutz SM; Sharma S; Lehrer RI; Cole AL; Cole AM
    FEBS J; 2007 Dec; 274(24):6477-87. PubMed ID: 18028423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of HIV-1 with RNA interference: a multiple shRNA approach.
    ter Brake O; Konstantinova P; Ceylan M; Berkhout B
    Mol Ther; 2006 Dec; 14(6):883-92. PubMed ID: 16959541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
    Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B
    J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.